{"database": "openregs", "table": "documents", "rows": [["FDA-2012-D-0307-0070", "FDA", "FDA-2012-D-0307", "Recommendations To Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Guidance for Industry; Availability", "Notice", "Notice of Availability", "2022-05-24T04:00:00Z", 2022, 5, "2022-05-24T04:00:00Z", "2022-05-25T03:59:59Z", "2022-05-25T01:01:14Z", "2022-11119", 0, 0, "09000064850dbd5c"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2012-D-0307-0070"], "units": {}, "query_ms": 63.31544590648264, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}